TABLE 1.
Phenotypic drug susceptibility profiles of 41 isolates resistant to ofloxacin and 21 ofloxacin-sensitive control isolates
| Pattern | Drug susceptibility patterna |
No. (%) of ofloxacin-resistant isolates | No. (%) of ofloxacin-sensitive isolates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INH | RIF | STR | EMB | PZA | KANA | ETHIO | CYCLO | TB1 | PAS | |||
| 1 | R | R | R | R | S | S | S | R | S | S | 0 | 3 (14.3) |
| 2 | R | R | R | R | S | R | R | S | S | S | 0 | 2 (9.5) |
| 3 | R | R | R | R | S | S | R | R | R | S | 0 | 2 (9.5) |
| 4 | R | R | R | R | S | S | R | S | S | R | 0 | 1 (4.8) |
| 5 | R | R | R | R | S | S | S | S | R | S | 0 | 1 (4.8) |
| 6 | R | R | R | R | S | S | S | S | S | S | 6 (14.6) | 12 (57.1) |
| 7 | R | R | R | R | R | S | S | S | S | S | 18 (43.9) | 0 |
| 8 | R | R | R | S | R | S | S | S | S | S | 3 (7.3) | 0 |
| 9 | R | R | R | S | S | S | S | S | S | S | 2 (4.9) | 0 |
| 10 | R | S | R | R | R | S | S | S | S | S | 2 (4.9) | 0 |
| 11 | R | R | R | R | R | R | R | R | R | S | 1 (2.4) | 0 |
| 12 | R | R | R | R | R | R | S | S | S | R | 1 (2.4) | 0 |
| 13 | R | R | R | R | R | S | R | S | R | S | 1 (2.4) | 0 |
| 14 | R | R | R | R | R | S | R | S | S | S | 1 (2.4) | 0 |
| 15 | R | R | R | R | R | S | S | S | S | R | 1 (2.4) | 0 |
| 16 | R | R | R | S | S | R | S | S | S | S | 1 (2.4) | 0 |
| 17 | R | R | R | S | S | S | R | S | S | S | 1 (2.4) | 0 |
| 18 | R | R | S | R | S | S | S | S | S | R | 1 (2.4) | 0 |
| 19 | S | S | R | S | S | S | S | S | S | S | 1 (2.4) | 0 |
| 20 | S | S | S | S | S | S | S | S | S | S | 1 (2.4) | 0 |
| Total | 41 (100) | 21 (100) | ||||||||||
a
Abbreviations: INH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutol; PZA, pyrazinamide; KANA, kanamycin; ETHIO, ethionamide; CYCLO, cycloserine; TB1, thioacetazone; PAS, para-aminosalicylic acid; R, resistant; S, sensitive.